Truqap is A New Drug Approved by FDA for Breast Cancer
Breast cancer remains one of the most common cancers worldwide, posing significant challenges to healthcare professionals and patients alike. In the quest for more effective treatments, a new drug, Truqap (capivasertib), has emerged as a promising option.
What is Truqap (Capivasertib)?
Truqap is a kinase inhibitor used to treat hormone receptor (HR)-positive or human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations. It works by blocking pathways that help the cancer cells survive and grow, thereby reducing cancer growth.
Clinical Trials and Approval
Truqap received FDA approval following positive results from the CAPItello-291 Phase III trial. In the trial, Truqap in combination with fulvestrant reduced the risk of disease progression or death by 50% versus fulvestrant alone. The median progression-free survival (PFS) for the Truqap with fulvestrant groups was 7.3 months versus the Faslodex group, which was 3.1 months.
Side Effects
Like all medications, Truqap can cause side effects. Common side effects include nausea, tiredness, vomiting, mouth sores, and changes in certain blood tests. Serious side effects include high blood sugar levels (hyperglycemia) and severe diarrhea, which can lead to dehydration. It’s important to consult with your healthcare provider for medical advice about side effects.
Cost of Truqap
The cost for Truqap oral tablet 160 mg is around $24,146 for a supply of 64 tablets, depending on the pharmacy you visit. Prices are for cash-paying customers and are not valid with insurance plans.
The cost of Truqap (capivasertib) is a topic of interest for many patients and healthcare providers. As a brand-name oral tablet prescribed for a certain type of breast cancer, the cost of Truqap can depend on several factors.
One of the primary reasons for the high cost of Truqap is that it is a brand-name drug and does not currently have a generic version. Brand-name drugs are typically more expensive because they are protected by patents, allowing the manufacturer to recoup the costs of research, development, and marketing before generic versions can be produced.
In addition, the cost of Truqap can vary depending on your treatment plan, your insurance coverage, the pharmacy you use, and whether Truqap has a savings program. For instance, the manufacturer of Truqap offers a savings program that can help eligible patients save on their prescription.
It’s also worth noting that the cost for Truqap oral tablet 160 mg is around $24,146 for a supply of 64 tablets, depending on the pharmacy you visit. These prices are for cash-paying customers and are not valid with insurance plans.
The Impact of Truqap on Breast Cancer Treatment
The approval of Truqap marks a significant milestone in the treatment of breast cancer. By targeting the PIK3CA/AKT1/PTEN-alterations, Truqap offers a new therapeutic option for patients with HR-positive or HER2-negative locally advanced or metastatic breast cancer. This targeted approach could potentially improve the prognosis for these patients and enhance their quality of life.
Moreover, the successful clinical trial of Truqap underscores the importance of continued research and innovation in the field of oncology. It serves as a testament to the potential of kinase inhibitors in cancer treatment and paves the way for the development of more targeted therapies in the future.
